Male Circumcision for HIV Prevention in Rakai, Uganda
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00425984 |
Recruitment Status :
Completed
First Posted : January 24, 2007
Last Update Posted : August 24, 2007
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
HIV Infections Herpesvirus 2, Human Syphilis Genital Diseases, Male | Procedure: Adult male circumcision | Phase 3 |
South Africa has one of the most severe and fast-growing HIV epidemics in the world. Adult male circumcision may be an effective preventive measure to slow the spread of HIV and other STIs. This study will assess the efficacy of circumcision in HIV uninfected men in preventing HIV and STI acquisition.
This study will have two stages. In the first stage, 200 men will be enrolled into a study of the acceptability, feasibility, and safety of circumcision. Frequent postoperative follow-up will occur to determine rates of healing and complications. After assessment of those enrolled in Stage 1, Stage 2 enrollment will begin. Stage 2 will determine the efficacy of circumcision in preventing HIV acquisition. In both stages, HIV uninfected men will be randomly assigned to have either immediate circumcision or possible circumcision 2 years following Stage 2 study entry. The participants not receiving immediate circumcision will be offered circumcision after completion of 2 years of follow-up study, provided there is evidence of the efficacy of this procedure at that time. If efficacy is still unknown after 2 years of follow-up, participants will be given the option of circumcision at the completion of the trial.
Postoperative follow-up visits will be scheduled between 24 to 48 hours, 5 to 9 days, and 4 to 6 weeks. At each postoperative visit, participants will be questioned about symptoms suggestive of complications, and the area operated on will be inspected. Participants will be asked about resumption of sexual intercourse, and those who have resumed sexual intercourse will be asked about condom use. Study visits will be also conducted regarding risk behaviors and symptoms of STIs, and these will occur sometime between Weeks 4 to 6, and at Months 6, 12, and 24 post-enrollment. At each study visit, assessment of circumcision status and penile pathology; blood, urine, and penile swabs collection; and HIV testing will occur, and counseling and health education will be provided.
Study Type : | Interventional (Clinical Trial) |
Enrollment : | 5000 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Prevention |
Official Title: | Randomized Trial of Male Circumcision for HIV Prevention, Rakai, Uganda |
Study Start Date : | August 2002 |
Study Completion Date : | December 2006 |
- HIV acquisition
- safety of circumcision
- Sexually transmitted infections
- sexual risk behaviors
- acceptability

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 15 Years to 49 Years (Child, Adult) |
Sexes Eligible for Study: | Male |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- HIV uninfected
- Willing to receive HIV results
- Willing to be circumcised
- Parent or guardian willing to provide informed consent if applicable
- Hemoglobin of 8 grams/dl or less
- Intend to stay in Rakai, Uganda, for at least 1 year and are available for follow-up for 1 year
Exclusion Criteria:
- Already circumcised or partially circumcised
- Anatomical abnormality of the penis (e.g., hypospadias, severe phimosis) that may put the participant at risk if circumcised
- Medical conditions that require therapeutic circumcision
- Medical condition that contraindicates surgery or use of local anesthesia

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00425984
Uganda | |
Rakai Health Sciences Program, P.O. Box 279 | |
Kalisizo Town, Rakai, Uganda |
Principal Investigator: | Ronald H. Gray, MD | Department of Population, Family and Reproductive Health Sciences, Bloomberg School of Public Health, Johns Hopkins University |
Other Publications:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
ClinicalTrials.gov Identifier: | NCT00425984 |
Other Study ID Numbers: |
U1AI171-1-02 U1 AII 171-01-02 U1 AI 171-1-02 |
First Posted: | January 24, 2007 Key Record Dates |
Last Update Posted: | August 24, 2007 |
Last Verified: | August 2007 |
HIV Male circumcision Sexually transmitted infections Sexual risk behaviors Adult males Haemophilus ducreyi |
Human papillomavirus Rakai Uganda HIV seronegativity HPV STI |
Syphilis Genital Diseases Genital Diseases, Male Infections Communicable Diseases Sexually Transmitted Diseases Urogenital Diseases |
Treponemal Infections Spirochaetales Infections Gram-Negative Bacterial Infections Bacterial Infections Bacterial Infections and Mycoses Sexually Transmitted Diseases, Bacterial Male Urogenital Diseases |